$EVT (-1,64 %) announces the sale of its plant in Toulouse for USD 300-640 million. Probably necessary to have enough cash. Unfortunately, terrible figures were announced immediately afterwards. I should have been slightly in the black beforehand. Well, you're always smarter afterwards. Waiting is the motto here. Perhaps the royalties for the biosimilars will give the company a boost in the future. No buy recommendation for the time being in my opinion.